BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36520422)

  • 1. External Validation of the Ovarian-Adnexal Reporting and Data System (O-RADS) Lexicon and the International Ovarian Tumor Analysis 2-Step Strategy to Stratify Ovarian Tumors Into O-RADS Risk Groups.
    Timmerman S; Valentin L; Ceusters J; Testa AC; Landolfo C; Sladkevicius P; Van Holsbeke C; Domali E; Fruscio R; Epstein E; Franchi D; Kudla MJ; Chiappa V; Alcazar JL; Leone FPG; Buonomo F; Coccia ME; Guerriero S; Deo N; Jokubkiene L; Kaijser J; Scambia G; Andreotti R; Timmerman D; Bourne T; Van Calster B; Froyman W
    JAMA Oncol; 2023 Feb; 9(2):225-233. PubMed ID: 36520422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women.
    Hiett AK; Sonek JD; Guy M; Reid TJ
    Ultrasound Obstet Gynecol; 2022 May; 59(5):668-676. PubMed ID: 34533862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Performance of Ultrasonography-Based Risk Models in Differentiating Between Benign and Malignant Ovarian Tumors in a US Cohort.
    Yoeli-Bik R; Longman RE; Wroblewski K; Weigert M; Abramowicz JS; Lengyel E
    JAMA Netw Open; 2023 Jul; 6(7):e2323289. PubMed ID: 37440228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort.
    Landolfo C; Bourne T; Froyman W; Van Calster B; Ceusters J; Testa AC; Wynants L; Sladkevicius P; Van Holsbeke C; Domali E; Fruscio R; Epstein E; Franchi D; Kudla MJ; Chiappa V; Alcazar JL; Leone FPG; Buonomo F; Coccia ME; Guerriero S; Deo N; Jokubkiene L; Savelli L; Fischerova D; Czekierdowski A; Kaijser J; Coosemans A; Scambia G; Vergote I; Timmerman D; Valentin L
    Ultrasound Obstet Gynecol; 2023 Feb; 61(2):231-242. PubMed ID: 36178788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External Validation of O-RADS US Risk Stratification and Management System.
    Hack K; Gandhi N; Bouchard-Fortier G; Chawla TP; Ferguson SE; Li S; Kahn D; Tyrrell PN; Glanc P
    Radiology; 2022 Jul; 304(1):114-120. PubMed ID: 35438559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O-RADS US Risk Stratification and Management System: A Consensus Guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee.
    Andreotti RF; Timmerman D; Strachowski LM; Froyman W; Benacerraf BR; Bennett GL; Bourne T; Brown DL; Coleman BG; Frates MC; Goldstein SR; Hamper UM; Horrow MM; Hernanz-Schulman M; Reinhold C; Rose SL; Whitcomb BP; Wolfman WL; Glanc P
    Radiology; 2020 Jan; 294(1):168-185. PubMed ID: 31687921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of O-RADS, GI-RADS, and IOTA simple rules regarding malignancy rate, validity, and reliability for diagnosis of adnexal masses.
    Basha MAA; Metwally MI; Gamil SA; Khater HM; Aly SA; El Sammak AA; Zaitoun MMA; Khattab EM; Azmy TM; Alayouty NA; Mohey N; Almassry HN; Yousef HY; Ibrahim SA; Mohamed EA; Mohamed AEM; Afifi AHM; Harb OA; Algazzar HY
    Eur Radiol; 2021 Feb; 31(2):674-684. PubMed ID: 32809166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses.
    Xie WT; Wang YQ; Xiang ZS; Du ZS; Huang SX; Chen YJ; Tang LN
    J Ovarian Res; 2022 Jan; 15(1):15. PubMed ID: 35067220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective external validation of IOTA three-step strategy for characterizing and classifying adnexal masses and retrospective assessment of alternative two-step strategy using simple-rules risk.
    Hidalgo JJ; Ros F; Aubá M; Errasti T; Olartecoechea B; Ruiz-Zambrana Á; Alcázar JL
    Ultrasound Obstet Gynecol; 2019 May; 53(5):693-700. PubMed ID: 30353585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O-RADS MRI: A Systematic Review and Meta-Analysis of Diagnostic Performance and Category-wise Malignancy Rates.
    Rizzo S; Cozzi A; Dolciami M; Del Grande F; Scarano AL; Papadia A; Gui B; Gandolfo N; Catalano C; Manganaro L
    Radiology; 2023 Apr; 307(1):e220795. PubMed ID: 36413127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review and Meta-Analysis of O-RADS Ultrasound and O-RADS MRI for Risk Assessment of Ovarian and Adnexal Lesions.
    Zhang Q; Dai X; Li W
    AJR Am J Roentgenol; 2023 Jul; 221(1):21-33. PubMed ID: 36722758
    [No Abstract]   [Full Text] [Related]  

  • 12. Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses.
    Cao L; Wei M; Liu Y; Fu J; Zhang H; Huang J; Pei X; Zhou J
    Gynecol Oncol; 2021 Jul; 162(1):107-112. PubMed ID: 33966893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of American College of Radiology Ovarian-Adnexal Reporting and Data System ultrasound to predict malignancy risk in adnexal lesions.
    Li Y; Shao G; Wu M; Zhang F; Zhang Y; Shao C
    J Obstet Gynaecol Res; 2024 Feb; 50(2):225-232. PubMed ID: 37990446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of adnexal lesions using photoacoustic imaging to improve sonographic O-RADS risk assessment.
    Zhu Q; Luo H; Middleton WD; Itani M; Hagemann IS; Hagemann AR; Hoegger MJ; Thaker PH; Kuroki LM; MCourt CK; Mutch DG; Powell MA; Siegel CL
    Ultrasound Obstet Gynecol; 2023 Dec; 62(6):891-903. PubMed ID: 37606287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of IOTA SR and O-RADS combined with CA125, HE4, and risk of malignancy algorithm to distinguish benign and malignant adnexal masses.
    Yang Y; Ju H; Huang Y
    Eur J Radiol; 2023 Aug; 165():110926. PubMed ID: 37418798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective external validation of IOTA methods for classifying adnexal masses and retrospective assessment of two-step strategy using benign descriptors and ADNEX: a Portuguese multicenter study.
    Borges AL; Brito M; Ambrósio P; Condeço R; Pinto P; Ambrósio B; Mahomed F; Gama JMR; Bernardo MJ; Gouveia AI; Djokovic D
    Ultrasound Obstet Gynecol; 2024 Mar; ():. PubMed ID: 38477149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Performance of the Ovarian-Adnexal Reporting and Data System (O-RADS) Ultrasound Risk Score in Women in the United States.
    Jha P; Gupta A; Baran TM; Maturen KE; Patel-Lippmann K; Zafar HM; Kamaya A; Antil N; Barroilhet L; Sadowski EA
    JAMA Netw Open; 2022 Jun; 5(6):e2216370. PubMed ID: 35679042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
    Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
    Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective comparative trial comparing O-RADS, IOTA ADNEX model, and RMI score for preoperative evaluation of adnexal masses for prediction of ovarian cancer.
    Poonyakanok V; Tanmahasamut P; Jaishuen A
    J Obstet Gynaecol Res; 2023 May; 49(5):1412-1417. PubMed ID: 36895122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving risk stratification of indeterminate adnexal masses on MRI: What imaging features help predict malignancy in O-RADS MRI 4 lesions?
    Wong BZY; Causa Andrieu PI; Sonoda Y; Chi DS; Aviki EM; Vargas HA; Woo S
    Eur J Radiol; 2023 Nov; 168():111122. PubMed ID: 37806193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.